An interventional study of Paracetamol and Placebo in Obesity, sponsored by Soroka University Medical Center. Status unknown at 1 site in Israel. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-03.
Sponsored by Soroka University Medical Center · Not applicable, Interventional, and Treatment
The investigators predict that giving patients paracetamol in the operative period will reduce their need for opioid pain reducers in the post operative setting.
This study is designed as a population-based prospective, double blind cohort study. A prospective cohort of patients admitted to laparoscopic gastric banding due to morbid obesity
STUDY GOALS
5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.
This study's planned enrollment of 220 is above the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →Soroka University Medical Center is the lead sponsor of 157 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Paracetamol
Drug: Placebo
Also known as: Perfalgan
amount of morphine
The primary outcome will be the comparison amount of morphine injected in each group until discharge
Time frame: Until discharge (participants will be followed for the duration of hospital stay, an expected average of 3 days)
Complication during treatment of patient in PACU:
Complication during treatment of patient in PACU, including: * Respiratory complications (respiratory support, need for ICU, etc) * Cardiovascular complications (hemodynamic instability, inotropic support ) * Gastrointestinal complications (nausea and vomiting tested by PONV scale, need to use antiemetic drugs) * Incidence of urinary retention and need for catheterization * Pruritus
Time frame: Until discarge from PACU (participants will be followed for the duration of PACU stay, an expected average of 2 hours)
Time discharging from PACU
Time frame: Until discharge from PACU (participants will be followed for the duration of PACU stay, an expected average of 2 hours)
Length of hospitalization
Time frame: Until discharge from hospital (participants will be followed for the duration of hospital stay, an expected average of 3 days)
Complications during hospitalization.
Complications during hospitalization, including : * Septic complications * Respiratory, cardiac or other complications
Time frame: Until discharge from hospital (participants will be followed for the duration of hospital stay, an expected average of 3 days)
This study is status unknown, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Soroka University Medical Center